Anti-PDL1 chimeric switch receptor modified T-cell therapy - Marino Biotechnology

Drug Profile

Anti-PDL1 chimeric switch receptor modified T-cell therapy - Marino Biotechnology

Alternative Names: Anti-PD-L1 CSR T cells - Marino Biotechnology; Anti-PDL1 chimeric antigen receptor T-cell therapy - Marino Biotechnology; Autologous anti- PD-L1 CSR T cells - Marino Biotechnology

Latest Information Update: 21 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Marino Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action CD274 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma; Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Solid tumours (Metastatic disease, Recurrent) in China (IV) (NCT02930967)
  • 01 Jul 2016 Phase-I clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater) in China (IV) (NCT02930967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top